tert-butyl (1R,5S,9r)-9-((6-((2-chloro-4-cyanophenyl)amino)-5-methylpyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate | 1148005-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (1R,5S,9r)-9-((6-((2-chloro-4-cyanophenyl)amino)-5-methylpyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate
• CAS: 1148005-81-5
• 化学式: C₂₄H₂₈ClN₅O₄
• 分子量: 485.97
• InChiKey: ZHODOKDBUPKJHF-YRWFTTLQSA-N

物化性质

• 沸点：
  613.5±55.0 °C(predicted)
• 密度：
  1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.31
• 重原子数：
  34.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  109.6
• 氢给体数：
  1.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (1R,5S,9r)-9-((6-((2-chloro-4-cyanophenyl)amino)-5-methylpyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate 在 三氟乙酸 作用下， 生成
  参考文献：
  名称：

  Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists

  摘要：

  The design and synthesis of two conformationally restricted oxazabicyclo octane derivatives as GRP119 agonists is described. Derivatives of scaffold C, with syn configuration, have the best overall profiles with respect to solubility and in vivo efficacy. Compound 25a was found to have extremely potent agonistic activity and was orally active in lowering blood glucose levels in a mouse oral glucose tolerance test at a dose of 0.1 mg/kg.[GRAPHICS](C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.047
• 作为产物：
  描述：

  tert-butyl (1R,5S,9r)-9-hydroxy-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate 在 potassium tert-butylate 、 sodium hydride 作用下， 生成 tert-butyl (1R,5S,9r)-9-((6-((2-chloro-4-cyanophenyl)amino)-5-methylpyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate
  参考文献：
  名称：

  Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists

  摘要：

  The design and synthesis of two conformationally restricted oxazabicyclo octane derivatives as GRP119 agonists is described. Derivatives of scaffold C, with syn configuration, have the best overall profiles with respect to solubility and in vivo efficacy. Compound 25a was found to have extremely potent agonistic activity and was orally active in lowering blood glucose levels in a mouse oral glucose tolerance test at a dose of 0.1 mg/kg.[GRAPHICS](C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.047

文献信息

• [EN] BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'HÉTÉROCYCLES BICYCLIQUES PONTÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2010114958A1

  公开（公告）日：2010-10-07

  The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.

  本发明涉及桥环双环杂环衍生物，包含桥环双环杂环衍生物的组合物，以及利用桥环双环杂环衍生物治疗或预防肥胖、糖尿病、代谢紊乱、心血管疾病或与患者GPCR活性有关的疾病的方法。
• [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2009055331A3

  公开（公告）日：2009-07-30